Please login to the form below

Not currently logged in
Email:
Password:

New drug matches chemo performance

Swiss pharmaceutical company, Roche, has revealed that new data will be presented at the WCGI showing that patients taking capecitabine can live up to five years after bowel cancer surgery

Swiss pharmaceutical company, Roche, has revealed that new data will be presented at the World Congress on Gastrointestinal Cancer (WCGI) showing that patients taking capecitabine can live up to five years after bowel cancer surgery.

Marketed by Roche under the brand name, Xeloda, capecitabine is proving to be as efficacious at sustaining a patient's post cancer operative life span as current treatments. Currently, patients who undergo bowel cancer surgery will be required to visit hospitals on a regular basis to complete courses of chemotherapy, administered as an intravenous (IV) therapy option.

Roche says that Patients who take capecitabine, which is already approved in 100 countries as a cancer medication, will not have to go through a long and regular course of IV chemotherapy. According to the company, the medicine could help clinicians fulfil the pledges of the Cancer Reform Strategy by allowing patients to be treated in the comfort and dignity of their own homes.

"These data confirm that capecitabine is an excellent treatment option for patients, both in terms of survival and convenience," said Jim Cassidy, professor of oncology at the Beaston Oncology Centre in Glasgow.

"Now that we have long-term evidence showing that capecitabine is at least as effective as 5-FU/FA, this supports the case for us to update our clinical practice."

27th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics